Evaluation of the effect of citalopram and ceftriaxone on neuropathy caused by vincristine in mice

Abstract

Introduction: One of the main side effects of vincristine is neuropathy and There are several mechanisms (increased NMDA grade, increased interferon alpha and interleukin-beta) in vincristine-induced neuropathy. Aim: The aim of the present study was to evaluate the effect of citalopram and ceftriaxone on vincristine-induced neuropathy in mice. Materials and Methods: 72 mice were in weight ranges of 25 to 35 chosen into 9 groups of 8 and Different doses of ceftriaxone (25, 50, 100 mg/kg, ip) and citalopram (5, 10, 20 mg/kg, ip) and combined doses (ceftriaxone, 25 mg/kg, ip + citalopram 5 mg/kg, ip) ) infused for ten days, half an hour before the injection of vincristine.Tail flick test was used to evaluate different diets for hypersensitivity. At the end of the study serum levels of Malondialdehyde (MDA) and Total antioxidants capacity (TAC) were evaluated. Results: Different doses of ceftriaxone and citalopram resulted in significant effects on the reduction of vincristine-induced neuropathy especially on the 13 and 18 days (p<0.001). ceftriaxone (25 mg/kg, ip) plus citalopram (5 mg/kg, ip) decresed significant neuropathic pain on the same days (p<0.001). Expectedly vincristine significantly increased the level of MDA (P<0.01) Whereas high doses of ceftriaxone and citalopram significantly decreased MDA in comparison to the control group(P<0.05). TAC levels were also associated with a significant increased with ceftriaxone 100 mg/kg (P<0.01) and citalopram 5,10,20 mg/kg (respectively P<0.05 , P<0.001 , P<0.001). ceftriaxone plus citalopram significant decresed the level of MDA and increased TAC in comparison to the control group (respectively P<0.05 , P<0.001). Conclusion: Ceftriaxone and citalopram may be effective by inhibiting oxidative stress on the reduction of vincristine-induced neuropathy.